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Summary
Melanoma is an aggressive and highly metastatic type of skin cancer where the design of new therapies is of utmost importance
for the clinical management of the disease. Thus, we have aimed to investigate the mode of action by which a novel methylated
analogue of L-Mimosine (e.g., L-SK-4) exerts its therapeutic potency in an in vitro model of malignant melanoma. Cytotoxicity
was assessed by the Alamar Blue assay, oxidative stress by commercially available kits, ROS generation, caspase 3/7 activation
and mitochondrial membrane depolarisation by flow cytometry, expression of apoptosis-related proteins by western immuno-
blotting and profiling of lipid biosynthesis by a metabolomic approach. Overall, higher levels of ROS, sphingolipids and
apoptosis were induced by L-SK-4 suggesting that the compound’s therapeutic potency is mediated through elevated ROS levels
which promote the upregulation of sphingolipid (ceramide) biosynthesis thus leading to the activation of both extrinsic and
intrinsic apoptosis, in an experimental model of malignant melanoma.
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Introduction
Reactive oxygen species (ROS) are generated as by-products
of oxygen consumption in mitochondria and/or from other
exogenous sources such as pollutants, tobacco, xenobiotics,
radiation, etc. [1, 2].
The beneficial role of ROS has been demonstrated
multiple times in the literature like in the case of immune
response induction [3]. More specifically, activation of
surveillance receptors leads to elevation of ROS that is
essential for the release of pro-inflammatory cytokines
[interleukin 1β (IL-1β), tumor necrosis factor α
(TNFα) and interferon β (IFN-β)] which are required
for the activation and regulation of an appropriate im-
mune response. Consequently, low levels of ROS can
lead to immunosuppression by preventing activation of
an immune response [4–6]. Moreover, ROS can influ-
ence cell proliferation through regulation of cell cycle
progression by acting as second messengers capable of
mediating the phosphorylation and ubiquitination of
CDKs via activation of the EGF-receptor [7–9].
On the other hand, increased levels of ROS can cause un-
desirable effects. For instance, they contribute to carcinogen-
esis through lipid peroxidation, protein carbonylation and
DNA/RNA oxidative damage all of which can lead to genetic
instability and tumorigenesis [9–13]. However, excessive
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accumulation of ROS, in cancer cells, can lead to anti-
tumorigenic effects by means of rendering them vulnera-
ble to the activation of apoptotic cell death. Thus, cancer
therapeutic strategies are designed with the scope to in-
duce ROS generation and consequently trigger an apopto-
tic response [14, 15]. To this end, it has been previously
demonstrated that many chemotherapeutic drugs have the
capacity to inhibit the intracellular antioxidant response
and thus cause accumulation of ROS which allows for
drug-induced cytotoxicity [15]. Nevertheless, the main
disadvantage of such approach(es) is the lack of specific-
ity as chemotherapeutic agents cannot target selectively
cancer cells [13].
The anti-cancer activity of hydroxypyridone-based
(HOPO) metal chelators has been documented, in the past,
by others [16, 17] as well as by our research group [18].
More specifically, we have previously shown that treatment
of malignant melanoma (A375) cells with a novel N-substitut-
ed 3,4-HOPO compound (L-SK-4) can induce the activation
of both intrinsic and extrinsic apoptotic cascades as well as
perturbations in cell cycle and ROS homeostasis [18].
Interestingly, an immortalized, non-tumorigenic keratinocyte
cell line was shown to be more resistant to the action of L-SK-
4; thus, proving the compound’s specificity against its poten-
tial target. Consequently, we have employed an in vitro model
of malignant melanoma consisting of non-metastatic (A375
and B16F-10) as well as metastatic (VMM1 and Hs294T)
melanoma cell lines in addition to non-melanoma epidermoid
carcinoma (A431) and non-malignant immortalized melano-
cyte neighbouring keratinocyte (HaCaT) cells. The aim of this
study was to investigate the mode of action by which L-SK-4
activates the apoptotic response in order to delineate the un-
derlying mechanisms by which it exerts its previously de-
scribed therapeutic potency [18].
Materials and methods
Chemicals
SK-1, SK-2, SK-3,D-SK-4, L-SK-4 and SK-5 were previous-
ly synthesized, purified and characterized [18]. GSH,
resazurin sodium salt and Myriocin were purchased from
Sigma-Aldrich (St. Louis, MO, USA). All media and cell
culture material were obtained from LabTech International
Ltd. (East Sussex, UK). Bovine Serum Albumin (BSA) was
obtained fromBiosera (Boussens, France). Protease and phos-
phatase inhibitor cocktails were obtained from Roche (Base,
Switzerland). Polyvinylidene difluoride (PVDF) membranes
(0.45 and 0.2 μm) were purchased from Millipore (Bedford,
MA, USA). All solvents were of UHPLC optima grade or
better.
Cell lines
A375 and A431 cells were purchased from Sigma-Aldrich (St.
Louis, MO, USA). In addition, VMM1, Hs294T and B16F10
cells were obtained from LGC Standards (Middlesex, UK).
All cell lines were maintained in a humidified atmosphere at
37 °C, 5% CO2 and according to the provider’s recommended
culture conditions. All media and reagents were purchased
from Labtech (East Sussex, UK). All plasticware were obtain-
ed from Corning (Corning, NY, USA).
Determination of cell viability
Briefly, A375 cells were seeded in 100 μL/well into 96-
well plates and incubated overnight. On the following
day, cells were exposed to either GSH (1.5–3.0 mM) or
Myriocin (0–50 μM) with or without L-SK-4 (100 μM)
over different incubation periods while control cells were
incubated with complete medium only. The Alamar-blue
assay was utilized as previously described [18].
Determination of ROS
Cells were seeded in 60 mm dishes and then exposed to L-SK-
4 (100 μM) with or without pre-treatment with either GSH
(1.5 mM) or Myriocin (50 nM). Then, they were harvested
and washed twice with PBS after which, a single cell suspen-
sion of 106 cells/mL was prepared. Dihydrorhodamine 123
(DHR 123; 10 μM) was added in the suspension and incubat-
ed for 5 mins at 37 °C followed by addition of DAPI (1 μM),
in each sample, and further incubation for 5 mins. Data acqui-
sition and analysis of 10,000 events, for each sample, was
performed using a FACS Canto II flow cytometer (BD
Biosciences, San Jose, CA, USA). DAPI-positive cells were
excluded from further analyses.
Determination of apoptosis
The CellEvent Caspase 3/7 Green flow cytometry assay kit
was utilized for the detection of apoptosis according to the
manufacturer’s instructions. Briefly, cells were seeded and
allowed to adhere overnight in 60 mm dishes and then ex-
posed to L-SK-4 (100 μM) with or without pre-treatment with
either GSH (1.5 mM) or Myriocin (50 nM). Next, cells were
harvested and washed twice with PBS after which, a single
cell suspension of 106 cells/mL was prepared. Then, 0.5 μL of
CellEvent Caspase 3/7 Green detection reagent was added
into 0.5 mL of each cell suspension and samples were incu-
bated at 37 °C for 30 mins followed by addition of DAPI
(1 μM), in each sample, and further incubation for 5 mins.
Data acquisition and analysis of 20,000 events, for each sam-
ple, was performed using a FACS Canto II flow cytometer
(BD Biosciences, San Jose, CA, USA).
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Determination of mitochondria membrane
depolarization
The JC-1 staining solution was used according to the man-
ufacturer’s instructions. Following treatment with L-SK-4
(100 μM) with or without pre-treatment with myriocin
(50 nM), cells were harvested and washed twice in PBS.
Then, 0.3 μL of JC-1 (0.1 mg/mL) was added into 0.3 mL
of each cell suspension, in PBS, and samples were incubat-
ed at 37 °C for 30 mins. All cell suspensions were centri-
fuged at 1000 rpm for 5 mins and pellets were re-suspended
in fresh PBS. Data acquisition and analysis of 10,000
events, for each sample, was performed using a FACS
Canto II flow cytometer (BD Biosciences, San Jose, CA,
USA).
Preparation of cell lysates and protein determination
A375 cells were plated in 100 mm dishes and cultured over-
night at 37 °C. Next day, cells were treated with L-SK-4
(100 μM) with or without pre-treatment with either GSH
(1.5 mM) or myriocin (50 nM) for 24, 48 and 72 h. Cell
lysates were prepared and obtained as previously described
[18]. Protein content was determined by utilizing the BCA
protein assay kit (Thermo Scientific, Waltham, MA, USA),
according to the manufacturer’s protocols. Protein extracts
were stored at −20 °C until usage.
Western immunoblotting
Standard conditions were used as previously described [18].
All antibodies (e.g., anti-Caspases-8 and -9, anti-Apaf-1, anti-
BID, anti-FADD, anti-FAS, anti-BAX, anti-BAK and anti-
Tubulin) were purchased from Cell Signaling Technology
(Danvers, MA, USA) and utilized according to the manufac-
turer’s protocol.
Determination of lipid peroxidation content
A375 cells were plated in 100 mm dishes, cultured overnight
and next day were treated with L-SK-4 (100 μM). After
trypsinization, pellets were collected, re-suspended and soni-
cated before the TBARS Assay kit (Cambridge Bioscience
Ltd., Cambridge, UK) was utilized for the determination of
malondialdehyde (MDA) content according to the manufac-
ture’s protocol.
Determination of protein carbonyl content
A375 cells were plated in 100 mm dishes, cultured overnight
and next day were treated with L-SK-4 (100 μM). After
trypsinization, pellets were collected, resuspended and soni-
cated before the Protein Carbonyl Colorimetric Assay Kit
(Cambridge Bioscience Ltd., Cambridge, UK) was utilized
for the determination of protein carbonyl content according
to the manufacture’s protocol.
Determination of oxidative DNA damage content
A375 cells were plated in 100 mm dishes, cultured over-
night and next day were treated with L-SK-4 (100 μM).
After trypsinization, pellets were collected and the
dsDNA content was extracted using the PureLinK™
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA)
and then converted to ssDNA according to the manufac-
ture’s protocol. The DNA/RNA Oxidative Damage (High
Sensitivity) ELISA Kit (Cambridge Bioscience Ltd.,
Cambridge, UK) was utilized for the determination of 8-
oxo-2-deoxy guanosine (8-OHdG) content according to
the manufacture’s protocol.
Lipidomic extraction protocol
A375 cells were plated in 100 mm dishes and cultured
overnight at 37 °C. Next day, cells were treated with
L-SK-4 (100 μM) and then trypsinised and collected by
cent r i fugat ion at 2000 rpm for 3 mins a t 4 °C.
Approximately 3 × 106 cells were washed with ice-cold
PBS three times prior to extraction. Then, the cell pellet
was re suspended in 300 μL of the extraction buffer (di-
chloromethane/methanol (3:1 v/v) chilled to 4 °C) and cell
lysis was induced by snap freezing the samples in liquid
nitrogen for 1 min and thaw over ice. This was repeated 5
times to ensure complete cell lysis. Then, cell suspensions
were sonicated for 15 mins and ultra-centrifuged at
15,000 rpm for 15 mins. The entire supernatant was trans-
ferred to 1.5 mL Eppendorf and allowed to evaporate, at
RT, overnight under a fume hood. The dried down extracts
were reconstituted in 300 μL of isopropyl alcohol/ACN/
water (2:1:1), sonicated for 15 mins and ultra-centrifuged
at 15,000 rpm for an additional 15 mins before transferring
100 μL to 1.5 mL autosampler vial, caped and then subject-
ed to lipidomic characterization.
Lipidomic sample analysis
LC parameters: Chemical analysis was performed on a
Thermo Scientific Orbritap classic mass spectrometer hy-
phenated to a Dionex 3000 UHPLC with the autosampler
tray set to 4 °C. The separation was performed on a Waters
C18 CSH analytical column, 2 × 100 mm with a 1.7 μm
particle size. The column was maintained at 55 °C with a
flow rate of 400 μL/min. A binary buffer system was used
for the chromatographic separation. Buffer A was 60/40 (v/
v ACN/MillQ water) and Buffer B (90/10 v/v isopropyl
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alcohol and ACN) with 10 mM ammonium formate and
0.1% formic acid.
LC profile: Starting condition: 00.00 min 45% (B)→
11.00 min 65% (B)→ 20.00 min 99% (B)→ 24.00 min
99% (B)→ 24.25 min 45% (B)→ 28.50 min 45% (B).
Mass spectrometer: The HESI source condition was as
follows: Sheath gas flow: 50, Aux Gas flow: 13, Sweep gas
flow: 3. Spray voltage was set 3.5 kV, Capillary temperature
was set to 275. S-lens RF level was set to 50 and the temper-
ature of the HESI was set to 425 °C.
Mass spectral acquisition parameter: Scan range was set
from 300 to 2000 m/z at mass resolution of 140 K with a scan
rate of 1.6 scans/s with an automatic gain control of 1 × 106
with a maximum injection time of 100 ms. MS1 profiling in
positive polarity mode.
Peak table generations: Compound discoverer V2, the
alignment window was set to 0.25 mins with mass tolerance
of 5 ppm with (M-H)+ adducts only. Quality control and ex-
traction blanks were imbedded into the analysis for stability
assessment and background subtractions.
Statistical analysis
Data were expressed as mean values ± standard deviation
(SD) and comparisons were made between control and treated
groups. Statistical analyses were performed by one-way
ANOVAwith Tukey’s test for multiple comparisons, by using
the SPSS v.22 software, and statistical significance was set at
p < 0.05, p < 0.01 and p < 0.001. For the lipidomic analyses,
all multivariate data analyses were performed using the
metaboanalyst v3 web-based version (https://academic.oup.
com/bioinformatics/article/34/24/4313/5046255).
Results
The capacity of HOPOs to induce ROS production
A kinetic characterization of the ability of HOPO-based metal
chelators [1,2-HOPO (rac-SK-3), 2,3-HOPO (rac-SK-5), 3,4-
HOPO (rac-SK-2,D/L-SK-4) and hydroxypyranone (rac-SK-
1)] to induce ROS generation was evaluated in malignant
melanoma cells. Each compound was assessed at a range of
concentrations (25–500 μM) and over 3 time points (24, 48
and 72 h). Our results show that none of the rac-SK-1, rac-
SK-2, rac-SK-3 and rac-SK-5 compounds were able to in-
duce ROS generation (Figs. 1AI-III and VI). On the other
hand, two enantiomerically pure forms of an N-substituted-
3, 4-HOPO had the capacity to induce a significant elevation
of ROS at a concentration of 100 μM after 24 h of exposure
(Figs. 1AIV and V). In particular, when A375 cells were treat-
ed with 100 μM of L-SK-4, substantially increased levels of
ROS were maintained over the course of 72 h; whereas, in the
case of D-SK-4 there was only a slight and dose-dependent
elevation of ROS levels throughout the time of exposure
(Figs. 1AIV and V). Additionally, the decrease in ROS
induced-levels at higher concentrations (500 μM) suggested
that L-SK-4 has completely chelated the redox active metals
(e.g., Fe(III) and/or Cu(II)) that could be present in different
cellular organelles, therefore minimizing the ROS production
levels. These observations demonstrated the dual character of
L-SK-4, which at 100 μM can act as a pro-oxidant, whereas at
higher concentrations (500 μM) acts as an anti-oxidant.
Finally, under similar experimental conditions, we evaluated
the capacity of L-SK-4 to induce ROS generation against
A431 as well as non-tumorigenic HaCaT cells in an attempt
to document the selectivity of L-SK-4 against A375 cells. Our
observations revealed that ROS levels also affected both A431
and HaCaT cells upon treatment with L-SK-4 but at a signif-
icantly lower magnitude (Fig. 1B and C). Taken together, our
data indicate that L-SK-4 exerts a higher degree of potency in
inducing elevated ROS generation in A375 compared to A431
and HaCaT cells.
Effect of oxidative stress in lipids, proteins and DNA
Then, we sought to determine the nature of ROS generation by
means of assessing the content of lipid, protein and DNA ox-
idation levels. To this end, we firstly examined the levels of
malondialdehyde content (MDA; a marker of lipid peroxida-
tion) which were significantly increased as early as 24 h
(Fig. 2A). In addition, the levels of protein carbonyl (a
marker of protein oxidation; Fig. 2B) and 8-OHdG (a marker
of oxidative DNA damage; Fig. 2C) content showed a similar
pattern of increase but with statistical significance noted as
early as 48 h and throughout the entire time course respectively.
ROS inhibition by GSH
In subsequent experiments, we utilized glutathione (GSH; a
well-known ROS scavenger [19, 20]) in order to examine the
role of ROS inhibition under the same experimental condi-
tions. A dose-response curve was obtained, in A375 cells,
over a range of GSH concentrations (1.5–6.0 mM) at different
time points (24–72 h) for determining the optimum experi-
mental conditions of its usage (Fig. 3A). Our data indicated
that a GSH concentration of 1.5 mMwas well tolerated by the
cells as at higher concentrations (3 and 6 mM) a cytotoxic
effect was observed (Fig. 3A). Co-treatment of 1.5 mM
GSH with 100 μM of L-SK-4 almost abolished the cytotoxic
effect of the drug (Fig. 3B) due to inhibition of ROS produc-
tion (Fig. 3B and C). In addition, we examined the degree of
potency of L-SK-4 treatment in other melanoma cell lines
including brain (VMM1; Fig. 3D) and lymph node metastatic
melanoma (Hs294T; Fig. 3E) as well as murine non-
metastatic melanoma (B16F-10; Fig. 3F) cells. From our
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results, it was evident that treatment with L-SK-4 induced a
similar trend in increasing ROS levels, during the first 24 h,
which was sustained at each time point thereafter. Finally, co-
treatment with GSH and L-SK-4 also showed a significant
reduction in ROS levels in a manner, similar to that observed
in A375 cells (Figs. 3D-F).
Fig. 1 Induction of ROS generation by various hydroxypyridinone
compounds in melanoma (A375), non-melanoma epidermoid carcinoma
(A431) and non-tumorigenic keratinocyte (HaCaT) cells. (A) A375 cells
were exposed to a range of concentrations (0–500 μM) of (I) rac-SK-1,
(II) rac-SK-2, (III) rac-SK-3, (IV) L-SK-4, (V) D-SK-4 and (VI) rac-
SK-5 for 24, 48 and 72 h; (B)HaCaT and (C)A431 cells were exposed to
a range of concentrations (0–500μM) of L-SK-4 for 24, 48 and 72 h. Data
shown are means ± SD of 3 replicates from three independent experi-
ments. Asterisk (*), hashtag (#) or rhombus (◊) denote statistical signifi-
cance when compare to their respective control at p < 0.05. **, ## and ◊◊
denote statistical significance at p < 0.01 whereas ***, ###, ◊◊◊ at p < 0.001
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GSH prevents L-SK-4-induced apoptosis by ROS
Moreover, we determined the levels of apoptotic and necrotic
cell populations in A375, VMM1, Hs294T and B16F-10 cell
lines after exposure to L-SK-4, in the presence or absence of
GSH, by utilizing a flow cytometry-based approach. Overall,
our data showed a reduction in the levels of viable cells to-
gether with increased rates of apoptosis while levels of necrot-
ic cells remained relatively low (Figs. 4AI-III). Additionally, it
appeared that treatment with L-SK-4 was cytotoxic in the oth-
er melanoma cell lines as well including those of VMM1
(Online Resource 1; Fig. S1), Hs294T (Online Resource 2;
Fig. S2) and B16F-10 (Online Resource 3; Fig. S3); although
they were more resistant compared to A375 cells.
Furthermore, necrotic induction rather than apoptotic
was recorded in VMM1 (Online Resource 1; Fig. S1),
Hs294T (Online Resource 2; Fig. S2) and B16F-10
(Online Resource 3; Fig. S3) cells. However, co-
treatment with GSH had a beneficial effect as it reduced
the levels of both apoptotic and necrotic cell popula-
tions. Finally, we aimed to identify key apoptotic pro-
teins capable of modulating the intrinsic and extrinsic
Fig. 2 The effect of L-SK-4-induced ROS generation on lipids, proteins
and DNA in melanoma cells. (A) Malondialdehyde (MDA), (B) protein
carbonyl and (C) oxidative DNA damage (8-OHdG) contents upon treat-
ment of A375 cells with 100 μM of L-SK-4 for 24, 48 and 72 h. Data
shown are means of ± SD of 3 replicates from three independent exper-
iments. Asterisk (*), denotes statistical significance when compare to
their respective control at p < 0.05. ** denotes statistical significance at
p < 0.01 whereas ***at p < 0.001
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apoptotic cascades in response to L-SK-4 treatment
(Fig. 4B). To this end, we evaluated the expression levels
of i) cleaved and full length Caspase-8 (indicative of extrinsic
apoptosis), ii) cleaved and full length Caspase-9 (indicative of
intrinsic apoptosis), iii) apoptotic protease-activating factor-1
(Apaf-1; indicative of intrinsic apoptosis) and iv) BID (linker
of extrinsic and intrinsic apoptotic cascades). Overall, our results
indicated the activation of Caspase-8, BID, Caspase-9 andApaf-
1 (Fig. 4B) all of which have been previously reported to
eventually lead to activation of Caspase-3 and consequently
the execution of apoptosis [21–24]. In contrast, when cells were
co-treated with GSH, the levels of the above-mentioned proteins
were maintained at control levels, suggesting that inhibition of
ROS generation (and consequently accumulation) is strongly
associated with the activation of apoptosis (Fig. 4B). However,
at 48 h post co-treatment, the levels of the listed proteins were
increased; nonetheless, at a lesser extent compared to the L-SK-
4 treated groups.
Fig. 3 The effect of ROS quenching, by GSH, in melanoma cells. (A)
A375 cells were exposed to a range of GSH concentrations (1.5–3.0 mM)
for 24, 48 and 72 h; (B)A375 cells were treated with either 100 μM of L-
SK-4 or pre-treated with 1.5 mM of GSH, for 2 h, and then co-treated
with 1.5 mM of GSH and 100 μM of L-SK-4 for 24, 48 and 72 h; (C)
GSH scavenges L-SK-4-induced ROS generation in melanoma cell lines;
A375 cells were treated with either 100 μMof L-SK-4 or pre-treated with
1.5 mM GSH, for 2 h, and then co-treated with 1.5 mM of GSH and
100μMof L-SK-4 for 24, 48 and 72 h; ROS levels were analyzed by flow
cytometry and quantitated as ROS fold induction. Same experimental
conditions were followed for (D) VMM1; (E) Hs294T and (F) B16F-
10 melanoma cells. Data shown are means ± SD of 3–5 replicates from
three independent experiments. Asterisk (*), hashtag (#) or rhombus (◊)
denote statistical significance when compare to their respective control at
p < 0.05. **, ## and ◊◊ denote statistical significance at p < 0.01 whereas
***, ###, ◊◊◊ at p < 0.001
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Lipidomic profile of the L-SK-4 treated cells
In order to investigate further into how ROS generation mod-
ulates the apoptotic response, we performed a lipidomic pro-
filing analysis, in A375 cells, after a 24 h treatment with
100 μM L-SK-4. PCA analysis and visualization indicated a
planar separation between control, treated and quality control
samples. It was revealed that 1800 lipid MS features (detected
by MS1, n = 4) have been significantly dysregulated between
control and treatment groups (Online Resource 4; Fig. S4).
Partial least square-discriminate analysis (PLS-DA, 1 latent
variable) was then applied to identify the most statistically
significant features (VIP x > 1), recognizing 486 lapidated
features that were retained (Online Resource 5; Fig. S5).
Receiver operating curve (ROC) analysis using Monte-Carlo
cross validation was then applied to elucidate the top 40 most
significant features. From those, it was confirmed (by
matching the MS1; m/z and processing the features via the
bioinformatic platform; Thermo Scientific Lipid Search v4)
that the elevated lipid classes were associated with de novo
biosynthesis of sphingolipids with ceramides being the most
significant ones (Fig. 5 and Online Resource 6; Fig. S6).
The role of sphingolipids in ROS-induced apoptosis
According to the literature, elevation in ROS generation can
stimulate the release of ceramide species which can act as
second messengers for activating apoptosis [25]. In order to
validate if a ROS-driven elevation of ceramide levels could
induce apoptosis, we utilized Myriocin (an inhibitor of serine
palmitoyl transferase [26, 27]) as a treatment vehicle to inhibit
de novo biosynthesis of sphingolipids (Fig. 6A). Initially,
A375 cells were exposed to a range of Myriocin concentra-
tions (0–50 μM) over various time periods (24–72 h) for de-
termining the optimum experimental conditions of its usage
(Fig. 6B). As a result, A375 cells were treated with 100 μMof
L-SK-4 in the presence or absence of 50 nM Myriocin. As
expected, the viability levels of A375 cells co-treated with L-
SK-4 and Myriocin were significantly elevated implying that
the utilization of Myriocin partly rescued cells from the ob-
served L-SK-4-induced cytotoxicity (Fig. 6C).
Next, we sought to evaluate the effect of Myriocin on L-
SK-4-induced cell death by means of flow cytometry
(Fig. 7AI-III). A similar pattern was observed, in A375 cells
co-treated with L-SK-4 and Myriocin, by means of increased
levels of viable (Fig. 7AI) and decreased levels of apoptotic
cells (Fig. 7AII) while those of necrotic remained relatively
unaffected (Fig. 7AIII). The capacity of ceramide to activate
extrinsic apoptosis (by inducing FasL stimulation) has been
well documented in the literature [28, 29]. Therefore, we
aimed to examine the underlying mechanism(s) triggering ex-
trinsic apoptosis as a response to ceramide induction. For this
reason, we determined the protein expression levels of Fas and
Fas-associated death domain (FADD) as well as those of
Caspase-8 and BID, in A375 cells. According to our data,
treatment with L-SK-4 increased expression levels of Fas,
FADD, Caspase-8 and BID, an effect which was significantly
minimized after co-treatment with Myriocin; thus suggesting
a role of ceramide in modulating the activation of extrinsic
apoptosis in A375 cells (Fig. 7B.
Finally, we attempted to further investigate into the effect
of increased sphingolipid biosynthesis on the activation of
intrinsic apoptosis. For this reason, we utilized flow cytometry
and western immunoblotting-based approaches in order to
examine levels of mitochondrial membrane depolarization
(ΔΨm) (by utilizing JC-1 as a marker of mitochondrial dys-
function; [30, 31]) (Fig. 8A) as well as those of Apaf-1,
Caspase 9 and pro-apoptotic regulators BAX and BAK re-
spectively (Fig. 8B and C). According to our results, treatment
with 100 μM of L-SK-4 induced a dramatic depolarization of
mitochondria while co-treatment with Myriocin re-polarized
the mitochondrial membrane, to a variable degree, in A375
cells (Fig. 8A). Furthermore, we examined the expression
levels of those proteins closely associated with the formation
of apoptosome; namely, Apaf-1 and Caspase-9 both of which
were shown to be activated under L-SK-4 treatment in A375
cells. In contrast, co-treatment with Myriocin caused a signif-
icant reduction in the expression of these proteins (Fig. 8B). In
addition, we examined the expression levels of pro-apoptotic
proteins BAX and BAK as markers of mitochondria degrada-
tion [32, 33] (Fig. 8C). Our data indicated their activation
under treatment with L-SK-4, an effect which was reversed
in the presence ofMyriocin, suggesting that ceramide can also
induce the activation of pro-apoptotic proteins; thereby, lead-
ing to the activation of downstream components of the intrin-
sic apoptotic cascade.
Discussion
Overexpression of anti-oxidant enzymes leads to an enriched
anti-oxidant capacity in human malignant melanoma cells
thus allowing them to quench excessive generation of ROS
[34, 35]. Previous studies comparing the anti-oxidant capacity
between humanmelanoma cells and normal melanocytes have
revealed that melanoma cells possess significantly lower con-
centrations of intracellular GSH, ferritin, ubiquinone and
Fig. 4 GSH prevents L-SK-4-induced apoptosis in melanoma cells. (A)
A375 cells were either treated with 100 μMof L-SK-4 or pre-treated with
1.5 mM of GSH, for 2 h, and then co-treated with 1.5 mM of GSH and
100 μMof L-SK-4 for 24, 48 and 72 h. A flow cytometry-based approach
was utilized for identifying and quantitating percent of (I) viable, (II)
apoptotic and (III) necrotic cell populations; (B) Expression levels of full
length and cleaved Caspases-8 and -9, BID as well as Apaf-1 proteins
were recorded by western immunoblotting
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Fig. 5 L-SK-4-induced sphingolipids biosynthesis in melanoma cells. A
lipidomic analysis-based sphingolipid de novo biosynthetic map shows
an up-regulation of sphingolipids biosynthesis after treatment with
100 μM of L-SK-4 (red bars) compared to the respective (untreated)
controls (green bars)
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catalase therefore making themmore vulnerable to extracellu-
lar peroxides [36–38]. In contrast, elevated levels of superox-
ide dismutase (SOD) and vitamin E makes them resistant to
oxidative stress while overexpression of NADPH oxidase 1
(induced by intracellular ROS) and superoxide anion are in-
volved in malignant transformation and invasiveness of mel-
anoma [39–41]. Consequently, it can be concluded that the
anti-oxidant capacity of melanoma cells is pivotal for their
growth and proliferation [42]. On the other hand, other studies
have suggested that induction of oxidative stress is responsible
for making the anti-oxidant enzymes unable to cope with the
toxic levels of ROS, thus leading to excessive ROS accumu-
lation, lipid peroxidation, protein carbonylation and oxidative
DNA damage all of which can trigger apoptotic cell death and
therefore can be the target of new therapeutic strategies in
malignant melanoma [39].
The capacity of metal chelators to exert an anti-cancer ac-
tivity has been reported in a variety of in vitro cancer models
[43–45]. In a previous study published by our group, we have
documented the anti-cancer ability of a newly synthesized
series of hydroxypyridinone-based analogues of L-Mimosine
in an in vitro model of malignant melanoma. From these com-
pounds, a methylated N-substituted hydroxypyridinone form
was shown to be the most cytotoxic by exerting a higher
potency against A375 than A431 and HaCaT cells [18].
Herein, we performed a kinetic determination of ROS induc-
tion in a series of HOPO-based analogues of L-Mimosine in
an attempt to characterize the mode of action of this class of
Fig. 6 The effect of Myriocin on L-SK-4-induced cytotoxicity in
melanoma cells. (A) Schematic presentation of Myriocin preventing
ceramide biosynthesis by inhibition of Serine Palmitoyl Transferase;
(B) A375 cells were treated with a range (0.01–50 μM) of Myriocin
concentrations for 24, 48 and 72 h; (C) A375 cells were treated with
either 100 μM of L-SK-4 or pre-treated with 50 nM of Myriocin, for
4 h, and then co-treated with 50 nM of Myriocin and 100 μM of L-SK-
4 for 24, 48 and 72 h. Data shown are means ± SD of 5 replicates from
three independent experiments. Asterisk (*), hashtag (#) or rhombus (◊)
denote statistical significance when compare to their respective control at
p < 0.05. **, ## and ◊◊ denote statistical significance at p < 0.01 whereas
***, ###, ◊◊◊ at p < 0.001
Invest New Drugs
Invest New Drugs
compounds. Our data suggest that both enantiomers (L- and
D-) of the compound have the ability to induce ROS genera-
tion with the L- one being more potent (4X) compared to
untreated control as well as showing a selectivity for A375
rather than HaCaT and A431 cells.
Co-treatment of GSH and L-SK-4 significantly rescued
A375, VMM-1, Hs294T and B16F-10 cells from apoptosis,
by reducing ROS levels. This can be attributed to the fact that
melanoma cells have generally low levels of GSH and thus are
not able to overcome the induction of high levels of ROS
generation caused by L-SK-4 [43]. Moreover, although induc-
tion of both necrosis and apoptosis were recorded, the magni-
tude of such potency was different among different melanoma
cell lines in a way where Hs 294 T, VMM-1 and B16F10 ones
weremore resistant compared to the A375 one. These findings
were validated by western immunoblotting revealing the acti-
vation of key apoptotic proteins involved in both intrinsic and
extrinsic apoptotic cascades. On the other hand, co-treatment
Fig. 7 Myriocin prevents L-SK-4-induced extrinsic apoptosis in
melanoma cells. (A) A375 cells were treated with 100 μM of L-SK-4
or pre-treated with 50 nM of Myriocin, for 4 h, and then co-treated with
50 nM of Myriocin and 100 μM of L-SK-4 for 24, 48 and 72 h. A flow
cytometry-based approach was utilized for identifying and quantitating
percent of (I) viable, (II) apoptotic and (III) necrotic cell populations; (B)
Expression levels of full length and cleaved Caspase-8 as well as BID,
FADD and FAS proteins were recorded by western immunoblotting
Fig. 8 Myriocin prevents L-SK-
4-induced intrinsic apoptosis in
melanoma cells. (A) A375 cells
were treated with either
100 μM L-SK-4 or pre-treated
with 50 nM of Myriocin, for 4 h,
and then co-treated with 50 nM of
Myriocin and 100 μM of L-SK-4
for 24, 48 and 72 h. A flow
cytometry-based approach was
utilized for quantitating mito-
chondrial membrane depolariza-
tion as the ratio of JC-1 aggre-
gates over JC-1 monomers.
Expression levels of (B) full
length and cleaved Caspase-9 as
well as Apaf-1 proteins in addi-
tion to (C) pro-apoptotic proteins
BAK and BAX were recorded by
western immunoblotting
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with GSH reversed this trend and consequently rescued cells
from apoptotic cell death indicating a key role of ROS in
modulating the apoptotic response. Our findings are in agree-
ment with other studies showing that metal chelators can in-
duce ROS-driven apoptosis [43] and co-treatment with GSH
can prevent apoptotic activation [46, 47].
In an attempt to look further into the underlying mecha-
nisms of how L-SK-4-induced generation of oxidative stress
modulates the apoptotic response, we employed a lipidomic
approach in A375 cells. A significant up-regulation of
sphingolipid levels was observed with emphasis on those of
sphinganine, sphingomyeline, ceramide, phosphatidyl cho-
line, phosphatidyl serine and plasmenyl phosphatidyl ethanol-
amine. These findings are in agreement with other studies
indicating that ROS elevation stimulates the biosynthesis
and release of ceramide lipids (as well as other sphingolipids)
via ceramide releasing enzymes resulting in generation of a
ceramide-enriched membrane [48–50]. Moreover, additional
experiments with Myriocin (an inhibitor of the first step of
ceramide biosynthesis) confirmed the validity of our observa-
tions as inhibition of ceramide synthesis led to the rescue of
cells by preventing apoptotic activation. Such preventive ac-
tion has been explored by other studies suggesting that cer-
amide (as a bioactive lipid molecule) can act as a second
messenger capable of activating directly or indirectly the ex-
trinsic and intrinsic apoptotic pathways respectively [51, 52].
To conclude, we have shown that an N-substituted-3.4-
HOPOwas the most potent metal chelator capable of inducing
cytotoxicity in various melanoma cell lines. Its suggested
mode of action involves increased ROS production resulting
in significantly increased levels of sphingolipids’ (ceramide)
biosynthesis which, in turn, can act as second messenger(s)
capable of mediating the intrinsic as well as extrinsic apopto-
sis thereby modulating the therapeutic response of this newly
synthesized L-SK-4 compound.
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